The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Clinical trial NCT05536102 · RECRUITING
Trial details
- NCT number
- NCT05536102
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-05
- Primary completion
- 2023-09-30
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.